Loading
Cancer often ruins families financially, and money worries make people skip treatment. Ask about finances at the first visit, as routinely as asking about allergies, and route people to assistance.
Financial toxicity is common, predicts non-adherence and worse outcomes, and is rarely assessed. Validated brief instruments (such as the COST measure) can be added to intake, with positive screens triggering referral to financial navigators, charity programmes, and benefit advice. This is cheap and addresses a cause of care fragmentation and abandonment in every health system, insured or not.
Shares Money after treatment: what the cost of cancer does once the treatment has finished, Patients lack understanding, navigation and agency, Prices and value.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps, Prices and value.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Patients lack understanding, navigation and agency, Fragmented care and guideline gaps.
Shares Screening for distress: what the thermometer can and cannot do, Money after treatment: what the cost of cancer does once the treatment has finished, Prices and value.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.